TDF Dose Adjustment VS. Switching to TAF in TDF-experienced CHB Patients With Renal Impairment
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Tenofovir is a nucleotide analog drug that works against both Human immunodeficiency virus
(HIV) and HBV. TDF and TAF are prodrug of Tenofovir. TAF has a higher plasma stability than
TDF, which makes TDF require a higher dose to get the concentration of drugs in the liver
equal to the amount of TAF.
Previous studies have shown the effects of TAF once daily and TDF once daily on kidney
function and bone mass. The efficacy of TAF in virus suppression is comparable to TDF, but
the effect on the kidneys and bone mass from TAF has less side effects than TDF. In addition,
changing the medication from TDF to TAF shows that kidney function tends to improve.
Hepatitis B patients taking TDF have adjusted their dosage due to impair renal function, for
example, from 1 time per day to every 48 hours or every 72 hours. This group of patients does
not have a clear evidence-based recommendation for choosing a reduced dose of TDF or change
to TAF. Therefore, the main objective of this study is to study patients with hepatitis B who
have taken TDF and have renal function impairment that have been adjusted. Taking the same
medicine with dose adjustment or changing the drug to TAF which treatment will more improve
the kidney function.